


## Supplemental Figures:

### Figure S1



### Figure S1. Plasma from vaccinated mice does

**not abrogate T cell responses.** Plasmas were

harvested from C57BL/6 mice that were vaccinated

with mRNA-spike (two doses). 400  $\mu$ L of plasma

were adoptively transferred via the intraperitoneal

route into BALB/c mice. On the following day, all

mice were immunized intramuscularly with 3  $\mu$ g of

an mRNA expressing SARS-CoV-2 spike; and T cell

responses were quantified by intracellular cytokine

staining (ICS) at day 21 post-vaccination. Naïve

plasmas were used as controls. Splenocytes were incubated with overlapping SARS-CoV-2

peptide pools for 5 hr at 37°C in the presence of GolgiStop and GolgiPlug to detect SARS-

CoV-2-specific CD8+ T cell responses (A) and CD4+ T cell responses (B). Two-tailed Mann


Whitney test was used. Data are from an experiment with 4 mice that received naïve plasma

and 5 mice that received post-vaccine plasma (week 2 post-boost); experiment was repeated

for a total of 2 times, with similar results; dashed lines represent the LOD. Error bars indicate

the SEM.

Figure S2




**Figure S2. Plasma from vaccinated mice abrogates cross-reactive (Omicron-specific) antibody responses.**

Plasmas were harvested from C57BL/6 mice that were vaccinated with mRNA-spike (two doses). 400  $\mu$ L of plasma was adoptively transferred via the intraperitoneal route into BALB/c mice. On the following day, all mice were immunized intramuscularly with 3  $\mu$ g

of an mRNA expressing SARS-CoV-2 spike (ancestral sequence); and cross-reactive Omicron-specific immune responses were quantified. Naïve plasmas were used as controls. (B) Recipient-derived Omicron-specific antibody. (C) Experimental layout for detection of antibody secreting cells specific for ancestral or Omicron spike. (D) Omicron-specific antibody secreting cells in bone marrow. (E-F) T cell responses were quantified by intracellular cytokine staining (ICS) at day 21 post-vaccination. Splenocytes were incubated with overlapping SARS-CoV-2 peptide pools (derived from the Omicron variant) for 5 hr at 37°C in the presence of


GolgiStop and GolgiPlug to detect SARS-CoV-2–specific CD8+ T cell responses (E) and CD4+ T cell responses (F). Two-tailed Mann Whitney test was used. Data are from an experiment with 4 mice that received naïve plasma and 5 mice that received post-vaccine plasma (week 2 post-boost); experiment was repeated for a total of 2 times, with similar results; dashed lines represent the LOD. Error bars indicate the SEM.

Figure S3



**Figure S3. A heterologous Omicron boost is not superior to a homologous ancestral vaccine boost.** (A) Experimental layout. C57BL/6 mice were immunized intramuscularly with 3  $\mu$ g of an mRNA expressing ancestral spike. After 3 weeks, mice were boosted with either an mRNA expressing ancestral spike, or an mRNA expressing Omicron spike. Immune responses were quantified. (B) Summary of SARS-CoV-2 spike-specific CD8 T cells. These CD8 T cells were specific for a conserved CD8 T cell epitope present in both ancestral and Omicron viruses (K<sup>b</sup>VL8). (C) Ancestral spike-specific antibody responses. (D) Omicron spike-specific antibody responses. (E) Ancestral spike-specific neutralizing antibody responses. (F) Omicron spike-specific neutralizing antibody responses. Wilcoxon matched-pairs signed rank test was used for panels B-D, comparing pre-boost and post-boost responses for each vaccine regimen. For all other plots, two-tailed Mann Whitney test was used. Data are combined from two experiments; one experiment with 6-7 mice per group and another experiment with 5 mice per group. Dashed lines represent the LOD (in one experiment the LOD was 25). Error bars indicate the SEM.

## Figure S4



## Figure S4. Boosting with mRNA

results in lower antigen

expression, relative to priming

with mRNA.

(A) Experimental

layout. BALB/c mice were

immunized intramuscularly with 3  $\mu$ g

of an mRNA expressing Luciferase

(mRNA-Luc). After 2 weeks, mice

were boosted with the same mRNA,

and luciferase expression was

quantified by IVIS.

(B)

Bioluminescence images at 6 hr.

(C)

Summary of transgene expression

by in vivo bioluminescence imaging.

BALB/c mice (with white coat) were

used for improved visualization of

luciferase. Two-tailed Mann Whitney



test was used. Data are from one

experiment with 10 quadriceps per

group (5 mice per group). Experiment was repeated for a total of 2 times, with similar results.

Error bars indicate the SEM.

Figure S5



**Figure S5. mRNA-Luciferase immunization induces luciferase-specific antibody responses.**

C57BL/6 mice were immunized intramuscularly with 3  $\mu$ g of an mRNA expressing Luciferase, and after 3 weeks, mice were boosted. We immunized another group of mice with a different vaccine platform expressing the same transgene (Ad5-Luciferase) or with an irrelevant control mRNA vaccine expressing a different antigen (mRNA-spike). Two weeks after boost, mice were bled, and luciferase-specific antibodies were quantified in plasma. These plasma samples were used in adoptive transfers in Figure 6. Luciferase-specific antibody

responses are shown. Data are from one experiment with 5 donor mice. Experiment was repeated for a total of 2 times, with similar results. Error bars indicate the SEM.